StageSeries F | Alive
Last Raised$31.34M | 3 yrs ago
Nuvaira is a privately held company headquartered in Minneapolis, MN. The company’s proprietary Nuvaira Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma, in a procedure called Targeted Lung Denervation (TLD). The Nuvaira Lung Denervation System is under clinical investigation and is not commercially available in the USA, and is CE Mark approved.
Missing: Nuvaira's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
ESPs containing Nuvaira
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Companies in this market are developing everything from digital spirometers to detect the onset of an asthma attack to wearable sleepwear that monitors for signs of distress.
Nuvaira named as Highflier among 8 other companies, including Qnovia, Kinaset Therapeutics, and ILC Therapeutics.
Missing: Nuvaira's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Nuvaira
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Nuvaira is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Nuvaira has filed 56 patents.
The 3 most popular patent topics include:
- Respiratory therapy
- Muscarinic antagonists
- Combination drugs
Respiratory therapy, Dosage forms, Drug delivery devices, Medical equipment, Medical treatments
Respiratory therapy, Dosage forms, Drug delivery devices, Medical equipment, Medical treatments
Latest Nuvaira News
Dec 19, 2022
Healio Interviews Disclosures: Criner reports receiving grants from AstraZeneca, Boehringer Ingelheim, Broncus Medical, Chiesi, Corvus, Genentech, Gilead, GSK, Fisher & Paykel Healthcare, Lilly, NIH-NHLBI, Novartis, Olympus, Pennsylvania Department of Health, Pfizer, Pearl, PneumRx, Pulmonx, Regeneron, Roche and Spiration; consultant fees from Almirall, AstraZeneca, Broncus Medical, BTG Specialty Pharmaceuticals, CSA Medical, GSK, Eolo Medical, Intuitive Surgical, Ion Pharmaceuticals, Mereo BioPharma, Nuvaira, PneumRx, Pulmonx, Regeneron and Sanofi; and equity interest from FreeFlow Medical and Pleural Dynamics. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact firstname.lastname@example.org . Back to Healio The 2023 Global Initiative for Chronic Obstructive Lung Disease report defines several changes regarding definitions, assessment tools and treatments for COPD, all of which underscore recent advances in the field. “COPD is not a stagnant disease,” Gerard J. Criner, MD, FACP, FACCP, director of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) International COPD conference, told Healio. “The report identifies disease-modification therapies because we’re improving outcomes and we’re changing mortality, which should give patients and clinicians hope that the field is improving on a trajectory for the better.” To learn more about the updates made in the 2023 GOLD COPD report, “Global Strategy for the Diagnosis, Management and Prevention of COPD,” Healio spoke with Criner about the key changes that were presented at the conference. Revised definitions, assessments One overarching significant change in the report is a revised definition of COPD that is more all-encompassing of the demographic that can develop COPD, according to Criner, who also serves as chair and professor of thoracic medicine and surgery at Lewis Katz School of Medicine at Temple University. “The modification of the definition acknowledged that it’s not just people who have been exposed to cigarette smoke but other types of exposures, such as biomass fuels ,” Criner said. “The definition also includes people who work in jobs that expose them to a variety of conditions or poor climate. Additionally, it addresses a variety of host factors that may occur in the U.S., as well as non-U.S., such as being born premature or having a lot of childhood infections.” Along with this change in definition, the report also gives more attention to the roles chronic bronchitis and mucus hypersecretion play in the development of COPD and the pathogenesis of airflow obstruction. The 2023 report also has more information on the role of imaging and CT in diagnosing and managing COPD, highlighting the fact that CT has become increasingly available, leading to greater understand of COPD phenotypes, severity and outcomes. The report specifically recommends considering CT for patients with COPD and: persistent exacerbations; FEV1 less than 45% predicted with significant hyperinflation; who meet criteria for lung cancer screening. “We have written more about imaging and the importance of imaging to detect abnormalities that may exist in people with COPD that doesn’t cause airflow obstruction in its earlier stages,” Criner said. “The changes reflect that the importance of imaging is more ubiquitous, especially since the imaging with lung cancer screening and people who have been smoke-exposed determine structural abnormalities that may occur and may indicate people who are at greater risk to develop airflow obstruction. “The hope is to determine factors that may contribute to COPD earlier in life, so we can intercede and maybe transform the development or alter the trajectory,” he added. Another important change in this year’s report is a switch from using the “ABCD Assessment Tool” to the “ABE Assessment Tool.” Groups C and D from the original tool are now combined into group E, representing patients who have a record of either two or more moderate exacerbations or one or more exacerbations that resulted in hospitalization. Criner told Healio this change makes for a more clinically relevant explanation of exacerbations. “This makes it simpler for a clinician, and if a patient has frequent exacerbations or has elevated peripheral blood eosinophil levels, then perhaps those patients should be added on an inhaled corticosteroid,” Criner said. “That’s based on more recent randomized control trials.” COPD management The report also contains details on the management of stable COPD with both pharmacologic and nonpharmacologic treatments to reduce symptoms and future risk for exacerbations. When discussing long-acting bronchodilators, Criner said another key change in the report is that it now recommends long-acting muscarinic antagonist (LAMA)/long-acting beta-agonist (LABA) combination therapy for most patients (Groups B and E) as initial therapy, with bronchodilators recommended for patients in Group A. With this update, the combination of LABA and an inhaled corticosteroid (ICS) is no longer recommended. “Based on more recent data from randomized control trials, we suggest that the initial use of long-acting bronchodilators in patients who are more symptomatic or exacerbation prone is warranted,” he said. Criner also told Healio that the 2023 report includes findings from two recent randomized clinical trials, IMPACT and ETHOS, which found that inhaled triple combination therapy of LABA, LAMA and ICS reduced all-cause mortality. “The use of triple inhaled therapy joins other therapy for select patient populations with COPD, such as long-term option, lung volume reduction surgery, smoking cessation and use of noninvasive ventilation,” Criner said. “Triple inhaled therapy in that select group of patients prone to moderate and severe exacerbations has a mortality benefit.” More information also was added to the report on the topics of preventive and surgical treatment of COPD emphysema. “It’s more robust in not only talking about therapies that are available, but therapies that are currently undergoing phase 3 trials, both U.S. and non-U.S., that may be applicable to patients with COPD, exacerbations or chronic mucus hypersecretion,” he said. “There is also more detail on the patient populations and treatments that lung transplant may offer patients with COPD and emphysema.” The latest evidence on COPD in relation to comorbidities — which commonly include cardiovascular diseases, lung cancer, osteoporosis, depression/anxiety and gastroesophageal reflux and, in general, should not change COPD treatment — and COVID-19 were also featured in this report, Criner said. Regarding COVID-19, the report includes guidance on when patients with COPD should be tested for COVID-19, maintaining treatment throughout the pandemic and when it is appropriate to use spirometry and remote patient follow-up. Looking ahead When asked about the key takeaway for doctors and clinicians in the field, Criner said the 2023 report strives to improve the health of patients with COPD in several ways. “We’re trying to move the field to look at it more encompassing of patients’ health by trying to define factors both in = and outside of the lung that are modifiable and treatable so we can overall further improve cases,” he said. For next year’s conference, Criner said he would like to target patients as well as more primary care physicians and pulmonologists. “The conference is geared toward translating it into clinical practice, but it still doesn’t reach the primary care physician or perhaps the busy clinical pulmonologist,” he said. “We’ll try to address that audience by spreading out the conference to more than 1 day, targeting areas based for the community physician, and overall try to digest this, bring it to the patient and make it more relevant.” For more information: References:
Nuvaira Frequently Asked Questions (FAQ)
When was Nuvaira founded?
Nuvaira was founded in 2008.
Where is Nuvaira's headquarters?
Nuvaira's headquarters is located at 3750 Annapolis Lane North, Minneapolis.
What is Nuvaira's latest funding round?
Nuvaira's latest funding round is Series F.
How much did Nuvaira raise?
Nuvaira raised a total of $176.02M.
Who are the investors of Nuvaira?
Investors of Nuvaira include Vertex Ventures HC, U.S. Venture Partners, Endeavour Vision, Lightstone Ventures, Versant Ventures and 9 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.